Why the study?
Very little data existed on coronary obstruction following transcatheter aortic valve implantation.
What are the predictive factors, management, and clinical outcomes of coronary obstruction following TAVI?
Population
44 patients with symptomatic coronary obstruction out of 6,688 undergoing TAVI
Comparison
Coronary obstruction patients vs control group of 345 patients
Design
Multicenter registry
Follow-up
Median 12 (2 to 18) months
Key result
Symptomatic coronary obstruction following TAVI was associated with lower-lying coronary ostia (10.6 vs 13.4 mm; p<0.001) and carried a 30-day mortality of 40.9%.
Authors
Loading...
May support pre-TAVI CT screening of coronary height; leaves open prospective trials of prevention before practice change.
Cohort (n=6,688)
Yes
What are the predictive factors, management, and clinical outcomes of coronary obstruction following TAVI?
Absolute Event Rate: 10.6% vs 13.4%
p-value: p=<0.001
Symptomatic coronary obstruction following TAVI is a rare (0.66%) but life-threatening complication associated with lower-lying coronary ostia, shallow sinus of Valsalva, female sex, and balloon-expandable valves, carrying a very high mortality rate despite successful treatment.
Ribeiro et al. (2013) conducted a cohort in Transcatheter aortic valve implantation (n=6,688). Coronary obstruction vs. No coronary obstruction was evaluated on Mean left coronary artery ostia height (p=<0.001). Symptomatic coronary obstruction following TAVI was associated with lower-lying coronary ostia (10.6 vs 13.4 mm; p<0.001) and carried a 30-day mortality of 40.9%.